Skip to main content
Evidence Based Longevity (EBL)Check what I take
← All protocols
C

Protocol

Ground flaxseed (30 g/day) for blood pressure

In a 6-month double-blind Neither the participants nor the people assessing them know who received the real treatment until the trial ends. trial in 110 people with peripheral artery disease, 30 g a day of milled flaxseed lowered systolic pressure about 10 mmHg against placebo An inactive substitute made to look like the real treatment, so participants cannot tell which one they received..

Grade C: human trials exist, but they are small, mixed or not yet repeated. This is not a finding that it does not work. How to read a grade →

Compare this record with another, side by side →

At a glance

In plain words

One six-month trial found ground flaxseed lowered blood pressure by about 10 points in people with poor leg circulation. When all the trials are combined, the drop is under 2 points. The trials did not measure heart attacks or strokes.

The letter, taken apart
What was measured
Blood pressure after 6 months.
How big
Systolic pressure was 1.77 mmHg lower in the pooled trials.Read from the summary of PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 25740909.
Who it applies to
Adults, mostly with raised blood pressure or artery disease. No trial measured events.
Safety
None identified in the trials.
The record in one view
Compared with
Placebo foods without flaxseed.
Certainty
Grade C, resting on: One large double-blind trial and two meta-analyses A study that pools the numbers from several trials into one combined estimate..
What would change this grade
Could rise to B with: Double-blind randomized trial of 30 g milled flaxseed. Who: Adults with hypertension, without artery disease. Measured: 24-hour ambulatory blood pressure. Length: At least 6 months.
Cost
No price recorded yet.
Sources
3 studies cited on this record, listed under Sources.
For clinicians
A one-page summary of this record that prints with a clinician's name and practice, folds to a plain-language patient handout, and gives a chart note to paste into the patient record: Printable summary and chart note.
Food
CSurrogate biomarker Grade C

In a 6-month double-blind trial in 110 people with peripheral artery disease, 30 g a day of milled flaxseed lowered systolic pressure about 10 mmHg against placebo. Meta-analyses found smaller pooled effects, about 1.8 mmHg across 14 trials and about 3.2 mmHg across 33 trials, with very high unexplained variation between trials. The large single-trial effect is not reproduced in the pooled trials, so the letter is C, the same standard applied to beetroot.

Why this letter

Why this gradeGrade C, small or unreplicated trials. The reasoning, and what the grade does not cover.
Why this grade

Grade C on blood pressure. One double-blind trial in peripheral artery disease found systolic pressure about 10 mmHg lower with flaxseed (Rodriguez-Leyva et al., 2013; PMID 24126178).

WHY NOT Bthe pooled effects are about 1.8 mmHg systolic across 14 trials (Khalesi et al., 2015; PMID 25740909) and 3.2 mmHg across 33 trials with heterogeneity How much the results of the pooled trials differ from each other. High heterogeneity makes a combined estimate less reliable. of 92.5 percent (Li et al., 2023; PMID 36622248), so the large effect is not reproduced; this follows the standard applied when beetroot was moved from B to C in October 2026.

WHAT THIS GRADE DOES NOT COVERcardiovascular events, which no cited trial measured. It also does not cover flaxseed oil or lignan extracts, which some pooled trials used instead of ground seed.

A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →

Who responds: this record's trial reading reports no subgroup that identifies who responds.

Evidence notes: randomized trial, meta-analysis

Endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. graded: Blood pressure (surrogate)

Last reviewed: November 2026

Evidence wanted

The trial that would change this grade.

DesignDouble-blind randomized trial of 30 g milled flaxseed
PopulationAdults with hypertension, without artery disease
Endpoint24-hour ambulatory blood pressure
DurationAt least 6 months

A positive trial of this shape, supported by further trials, would move this entry to B.

Why the current trials fall short

A second trial reproducing the 10 mmHg effect on 24-hour readings would carry it to B.

Clinical trials

ClinicalTrials.gov, the public registry run by the U.S. National Library of Medicine, lists studies that are recruiting volunteers. The link below searches it for Flaxseed among studies recruiting now. EBL has no relationship with any listed study and receives no payment for this link.

Search recruiting studies of Flaxseed on ClinicalTrials.gov

Dose, form and timing

What to track

Home or clinic blood pressure over months.

Safety

Safety evidence, by strength

No safety data. Each caution on this record, sorted by what it rests on.

Documented in human studies
Cautions resting on what randomized trials or large studies found in people.

None recorded.

Suspected from case reports
Harms reported in individual patients or uncontrolled observations, not confirmed by a trial.

None recorded.

Mechanistic only
Cautions reasoned from how it works, with no human harm data behind them.

None recorded.

Population cautions
Groups in whom it has not been studied, so its safety there is unknown.

None recorded.

No safety data

No safety data: EBL has found no trial or report of harm for this record. That is an absence of evidence, not a finding of safety.

Grade history

How this letter has changedLatest: No. 446 · November 2026 · First graded.
Grade history
No. 446 · November 2026 · First graded
Ground flaxseed (30 g/day) for blood pressure enters the food section: Grade C

New record in the food section. In a 6-month double-blind trial in 110 people with peripheral artery disease, 30 g a day of milled flaxseed lowered systolic pressure about 10 mmHg against placebo. Meta-analyses found smaller pooled effects, about 1.8 mmHg across 14 trials and about 3.2 mmHg across 33 trials, with very high unexplained variation between trials. The large single-trial effect is not reproduced in the pooled trials, so the letter is C, the same standard applied to beetroot.PMID 24126178 PMID 25740909 PMID 36622248

Every change to a letter on this site is dated and published. The full evidence log →

Sources

How this record was checked
Citations
Every paper cited on this page is matched to its PubMed record on every build.
Retractions
None of these papers is retracted or under a journal expression of concern. PubMed is checked again on every build.
Read against the papers
November 2026. By a language model (AI-assisted reading), not yet reviewed by a clinician.
Outside review
Not yet done. No reviewer outside EBL has checked this record.

What each of these checks can and cannot show: evidence integrity.

The evidence, in fullThree papers, each linked to its PubMed record.
The evidence

Rodriguez-Leyva et al. (Hypertension, 2013; PMID 24126178): FLAX-PAD, double-blind placebo-controlled randomized trial, 110 patients with peripheral artery disease, 30 g milled flaxseed in foods daily for 6 months; systolic pressure about 10 mmHg and diastolic about 7 mmHg lower than placebo. Khalesi et al. (Eur J Clin Nutr, 2015; PMID 25740909): meta-analysis of 14 controlled trials; systolic pressure 1.77 mmHg lower (95% CI 0.09 to 3.45) and diastolic 1.58 mmHg lower. Li et al. (Food Funct, 2023; PMID 36622248): meta-analysis of 33 trials, 2,427 participants; systolic pressure 3.19 mmHg lower (95% CI 2.24 to 4.15), heterogeneity I2 92.5 percent; larger effects with more than 20 weeks, 30 g a day or more, and hypertension.

How EBL searched for the trials (1 search)

The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.

Searched PubMed in November 2026. 35 records screened, 3 eligible for the graded claim.
Query: (flaxseed[tiab] OR linseed[tiab]) AND "blood pressure"[tiab] AND (randomized controlled trial[pt] OR meta-analysis[pt])
All 35 records screened by title. The 2023 meta-analysis of 33 trials (PMID 36622248) is the most recent pool and is on the record.
PubMed watch: does a new study change the grade? (nothing new)

No new paper matching the search behind this grade has been added to PubMed since November 2026.

Last run November 2026. A letter on EBL moves only after a logged review. A new paper never moves a letter by arriving: it is read, the answer is written here, and any change to the letter is published in the evidence log.

Who paid for these trials

For each trial behind a letter on this page, the funding its PubMed record lists. "No funder" means PubMed lists none, not that the trial had no funding.

  • Rodriguez-Leyva et al., 2013, Hypertension (PMID 24126178): PubMed lists funding from Canadian Institutes of Health Research.

Disclosure

Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.

Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy

© Evidence Based Longevity, Inc. All rights reserved

Medical disclaimer

These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.

Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →

Build 9b19d78, November 2026